Customer Publication

The implication of ROCK 2 as a potential senotherapeutic target via the suppression of the harmful effects of the SASP: Do senescent cancer cells really engulf the other cells?

Authors: Y. Dilber et al.

Journal: Cellular Signalling (2021)

Institution: Gazi University

Research Areas: Cell Research

Cell Lines: HeLa and A549 (HeLa - cervical cancer cell line; A549 - human lung adenocarcinoma cells)

Summary: Senescence-associated secretory phenotype (SASP) is responsible for chemotherapy adverse effects: drug resistance and the induction of cancer cell proliferation, migration, and invasion. Hence, developing senolytic/semomorphic drugs, targeting senescence cells, are important to improve cancer treatment outcome. In this work, Y. D. Simay with colleagues evaluated if Rho/Rho kinase pathway could be a target for potential drugs in doxorubicin-induced senescent cancer cell lines. Authors have shown that ROCK inhibitors (i.e. ROCK2) have the potential to be developed into semomorphic drugs as they change SASP composition and reduce senescence cell secretory activity. HoloMonitor M4 was used to study cell morphology (cell area, optical volume, and optical thickness).

Keywords: HoloMonitor M4, cell morphology, Senescent cell secretome, Chemotherapy-induced senescence, Rho/ROCK pathway, Senescence-associated secretory phenotype, Senotherapeutic

Read the article …

Phase Holographic Imaging PHI AB
Skiffervägen 48
224 78 Lund
+46 46 38 60 80

Phase Holographic Imaging PHI Inc.
265 Franklin Street Suite 1702
Boston, MA 02110
+1 617-963-5150


VAT: SE556542781101

Securities Identification

ISIN: SE0005504636
LEI: 549300JZR79QYESM6296

HoloMonitor® is a registered trademark
Copyright © 2012-2021
Phase Holographic Imaging PHI AB

Phase Holographic Image logo in white

PHI Theme 3.12.2